Preclinical studies have shown that combining MDM2 inhibitors with other therapeutic agents, such as chemotherapy or targeted inhibitors of MYC, can synergistically suppress tumor growth and overcome drug resistance [86]. This evidence concerns the gene MDM2 and neoplasm.